All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
An expert panel hosted by
Customizing first-line BTK inhibitors for CLL
with Gilles Salles, Paolo Ghia, and Francesc Bosch
Wednesday, October 23, 2024
18:30-19:30 BST
This independent educational activity is supported by Pharmacyclics LLC, an AbbVie Company and Janssen Biotech. All content is developed independently by the faculty. The funder is allowed no influence on the content of this activity.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
On 28 January 2019, ibrutinib, a Bruton’s tyrosine kinase (BTK) inhibitor, in combination with obinutuzumab was granted approval by the U.S. Food and Drug Administration (FDA) for the treatment of adults with previously untreated chronic lymphocytic leukemia or small lymphocytic lymphoma (CLL/SLL). This approval comes after the combination of ibrutinib and obinutuzumab was granted Priority Review status by the FDA on 17 October 2018.
The approval granted by the FDA was based on the positive results obtained from the international, multicenter, randomized phase III iLLUMINATE trial (NCT02264574) assessing ibrutinib in combination with obinutuzumab, in patients with previously untreated CLL/SLL. This study is one of the first to compare an anti-CD20, chemotherapy-free combination regimen to a chemo-immunotherapy for patients with CLL/SLL.
The phase III iLLUMINATE study demonstrated a statistically significant improvement in progression-free survival of ibrutinib in combination with obinutuzumab versus chlorambucil plus obinutuzumab as assessed by an Independent Review Committee (IRC), corresponding to a 77% reduction in the risk of progression or death in the ibrutinib arm (HR = 0.23; 95% CI, 0.15–0.37; P < 0.0001). The results of the phase III iLLUMINATE study was recently presented at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition, and published in The Lancet Oncology.
According to the drug manufacturers, the FDA approval of ibrutinib in combination with obinutuzumab provides “physicians and patients a new option to treat CLL and SLL without the need for chemotherapy”.
Understanding your specialty helps us to deliver the most relevant and engaging content.
Please spare a moment to share yours.
Please select or type your specialty
Subscribe to get the best content related to lymphoma & CLL delivered to your inbox